@CeleritasRe Great thread but I don't understand why this is - they have very obvious moats (that everyone knows) but haven't been able to capitalize on it (in a relative sense vs eg infra). Why do you think that is?
@viggy_krishnan@P_Remarks VCs seem to think AI isn't that useful for drug discovery though? Might make trials more efficient though (which is bearish tools)
@viggy_krishnan@InvestLikeBest Where this argument falls down is if Anthropic bills for $300 per month and is recognizing that revenue, and it's up to the company how much they use. Eventually that will lead to a reckoning.
@viggy_krishnan@InvestLikeBest The 90th percentile user is probably using 100x tokens the 50th percentile user at your average company - that creates an easy path for the next 2-3 years. How much the 90th percentile user usage expands does depend on what you're saying (which is harder).